Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) dropped 2.1% during mid-day trading on Tuesday . The company traded as low as $7.85 and last traded at $8.11. Approximately 42,680 shares traded hands during trading, an increase of 5% from the average daily volume of 40,795 shares. The stock had previously closed at $8.28.
Actuate Therapeutics Stock Down 1.4 %
The business's 50 day simple moving average is $8.37.
Institutional Trading of Actuate Therapeutics
An institutional investor recently bought a new position in Actuate Therapeutics stock. Northwestern University bought a new position in Actuate Therapeutics (NASDAQ:ACTU - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 27,778 shares of the company's stock, valued at approximately $207,000. Actuate Therapeutics comprises about 0.2% of Northwestern University's investment portfolio, making the stock its 5th largest position. Northwestern University owned about 0.14% of Actuate Therapeutics as of its most recent SEC filing.
About Actuate Therapeutics
(
Get Free Report)
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
See Also
Before you consider Actuate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.
While Actuate Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
